VenoStent GTM brain

VenoStent is developing a bioabsorbable external vascular wrap intended to improve dialysis access surgery outcomes.

category

Dialysis vascular access devices

market profile

  • text: AV fistula failure can require repeat procedures and interrupt a patient's dialysis access.
  • text: SelfWrap is investigational and the company says it is not available for sale in any country.
  • text: SAVE-FistulaS is a randomized, multicenter study evaluating safety and effectiveness of the wrap in new fistula creation.

personas

  • title: Vascular access surgeon
    pains:
    • New fistulas may fail to mature or remain usable, requiring repeat interventions.
    • A new implant must fit the surgical workflow and show clinical safety and effectiveness.
  • title: Dialysis program medical director or nephrologist
    pains:
    • Access failure disrupts treatment and can increase reliance on catheters.
    • Patients experience the burden of additional procedures and unreliable access.
  • title: Hospital vascular clinical trial investigator
    pains:
    • Needs eligible patients and a clear protocol for evaluating an investigational device.
    • Must monitor safety, fistula usability and follow-up outcomes.

icp

  • text: Hospitals and vascular access centers performing fistula creation for chronic kidney disease patients requiring hemodialysis.
  • text: US clinical research sites with vascular surgeons and eligible patients who can participate in an investigational AVF trial.

message pillars

  • text: Focus first on better renal dialysis access surgery outcomes.
  • text: Provide bioabsorbable external vascular support.
  • text: Emphasize the patient impact of failed access.

objections

  • objection: Can the hospital purchase SelfWrap now?
    response: No. The company describes it as investigational and not available for sale; discuss trial participation instead.
  • objection: Has efficacy been established for our patients?
    response: The randomized trial is designed to assess safety and effectiveness; review eligibility and results as they become available.
  • objection: How does it compare with existing fistula support?
    response: Evaluate the clinical evidence, material and regulatory status for each alternative; Laminate's VasQ is a permanent external support, unlike the bioabsorbable SelfWrap.

competitors

  • name: Laminate Medical Technologies
    website: https://www.laminatemedical.com/vasq/
    why: VasQ is an external support for surgically created AV fistulas, with a permanent rather than bioabsorbable design.
  • name: Humacyte
    why: Develops bioengineered vessels for hemodialysis access, an adjacent alternative approach to creating access rather than a direct wrap equivalent.

influencers

  • name: Tim Boire
    url: https://www.prnewswire.com/news-releases/venostent-completes-20-million-series-a-with-4-million-investment-from-norwest-venture-partners-302183962.html
    why: CEO and co-founder discussing clinical development and financing.

keywords

  • dialysis access failure
  • arteriovenous fistula maturation
  • vascular access support device
  • bioabsorbable vascular wrap
  • hemodialysis access clinical trial
  • fistula patency improvement

voice

  • Clinical and evidence-oriented
  • Patient-centered
  • Measured about investigational status

signals

  • text: A vascular center is researching fistula maturation or AV access patency.
  • text: A dialysis program seeks to reduce repeat interventions after access failure.

pricing

model: unknown

motion

unknown

channels

  • clinical trials
  • clinical publications
  • LinkedIn

confidence

medium

Founders

  • name: Tim Boire
    title: Founder
    role: Founder
    bio: President and CEO of VenoStent, Inc. I developed these novel smart polymeric biomaterials for vascular applications during my PhD at Vanderbilt University. Focus of the technology shifted to hemodialysis access applications after participating in the 2014 NSF I-Corps program. BS, Chemical & Biological Engineering and Biotechnology, Tufts University, 2008; PhD, Biomedical Engineering, Vanderbilt University, 2017. Worked in R&D at Genzyme Corporation, 2008 - 2011. Grew up in Nashua, NH.
  • name: Geoffrey Lucks
    title: Founder
    role: Founder
    bio: Co-founder & COO of pivotal trial-stage therapeutic medical device company developing bioabsorbable wraps to improve vascular surgery. Vandy MBA, UPenn Masters of Bioethics, UW-Madison UG Interested in tech and culture. Reading: the classics, religion, economics, finance, politics, philosophy, history, social sciences, etc. Born mellow and everywhere harshed.

Back to YC companies